Skip to main content

Legislating Social Media Addiction: Brainstorm Health

There’s a presidential primary debate on tonight (and I imagine at least a few readers will be checking in on it, given an expected focus on health care).

But let’s check in on a more low-key, and likely quixotic, policy quest aligned with the digital health space. A freshman U.S. Senator (Josh Hawley, a Missouri Republican), has proposed legislation that would ban “addictive” features on social media platforms.

The Social Media Addiction Reduction Technology Act (or, well, the SMART Act) would prevent some of the big tech names like Facebook, YouTube, and Twitter from using algorithmic means to feed on their very human users’ propensity for spending hours upon hours on said platforms (behavior that hasn’t exactly been linked with great mental health outcomes).

This might include the use of auto-play videos, or “infinite scrolling” (wherein your digital wormhole literally has no end), or programmable behavior encouraging users to constantly engage.

Whether such a piece of legislation has a snowball’s chance in passing – and even if it does, whether it would pass constitutional muster – well, that’s a whole different story. But perhaps one that will appear in the endless social media loop.

Read on for the day’s news.

Sy Mukherjee, @the_sy_guy, sayak.mukherjee@fortune.com



from Fortune https://ift.tt/2GC2bWS

Comments

Popular posts from this blog

Photo finish: Crashing sales force Olympus to sell iconic camera business

Sometimes, the vicissitudes of capitalism force companies to exit the businesses for which they’re best known. Olympus, once a leading light in the photography industry, is now joining that list. On Wednesday, the company said it planned to quit its 84-year-old camera business. The imaging giant, known for its once-pervasive digital cameras, agreed to sell off the declining unit by year’s end. Japan Industrial Partners, a private equity firm best known for buying Sony’s struggling Vaio computer line in 2014, agreed to purchase the business. Terms of the deal were not disclosed. A glance at Olympus’s financial statements provides all the rationale for the divestiture; as at rival manufacturers, camera sales have plummeted over the past decade. For the fiscal year ended March 31, Olympus’s camera unit declined 10% versus the year prior to  ¥43.6 billion, or $407 million. The unit’s sales have collapsed by three-quarters from a decade ago, when the company brought in ¥175 billion, or $

WHO says common steroids can slash death risk for the sickest coronavirus patients

Our mission to help you navigate the new normal is fueled by subscribers. To enjoy unlimited access to our journalism,  subscribe today . An old drug can learn new tricks during the coronavirus pandemic. That’s the main takeaway from the World Health Organization (WHO) in a new analysis of corticosteroids—a class of drugs which have existed for dozens of years and are far cheaper than new, experimental COVID treatments in development—suggesting that drugs like dexamethasone can slash the chances of COVID-19 related deaths by as much as 35% in the sickest patients. The WHO analysis of coronavirus drugs encompassed seven separate studies. And while an analysis of this sort—what’s called a “meta-analysis”—isn’t as rigorous as other types of trials like a randomized controlled study, the data are compelling. Corticosteroids have a very different action mechanism from many of the other coronavirus drugs in development. COVID-19 is a peculiar disease. Some who have been infected may be